Canada markets closed

Arbutus Biopharma Corporation (0SGC.L)

LSE - LSE Delayed Price. Currency in USD
Add to watchlist
2.7400+0.0180 (+0.66%)
At close: 07:02PM BST
Currency in USD

Valuation Measures4

Market Cap (intraday) N/A
Enterprise Value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 2.09
52-Week Change 3-7.00%
S&P500 52-Week Change 322.43%
52 Week High 33.1400
52 Week Low 31.7000
50-Day Moving Average 32.4452
200-Day Moving Average 32.3474

Share Statistics

Avg Vol (3 month) 31.41k
Avg Vol (10 day) 32.48k
Shares Outstanding 5N/A
Implied Shares Outstanding 6N/A
Float 8115.8M
% Held by Insiders 123.34%
% Held by Institutions 143.47%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 4N/A
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-956.64%

Management Effectiveness

Return on Assets (ttm)-28.70%
Return on Equity (ttm)-59.99%

Income Statement

Revenue (ttm)18.14M
Revenue Per Share (ttm)0.11
Quarterly Revenue Growth (yoy)-65.70%
Gross Profit (ttm)N/A
EBITDA -76.63M
Net Income Avi to Common (ttm)-72.85M
Diluted EPS (ttm)-0.7050
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)126M
Total Cash Per Share (mrq)0.7
Total Debt (mrq)8.72M
Total Debt/Equity (mrq)8.23%
Current Ratio (mrq)5.87
Book Value Per Share (mrq)0.62

Cash Flow Statement

Operating Cash Flow (ttm)-85.94M
Levered Free Cash Flow (ttm)-51.58M